Evidence map›Paper›PMID 28661427›Full record

ArticleAntioxidants (Basel, Switzerland)2017

Deletion of TXNIP Mitigates High-Fat Diet-Impaired Angiogenesis and Prevents Inflammation in a Mouse Model of Critical Limb Ischemia.

Sally L Elshaer, Islam N Mohamed, Maha Coucha, Sara Altantawi, Wael Eldahshan, Megan L Bartasi, Ahmed Y Shanab, Renee Lorys, Azza B El-Remessy

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. The multi-faced role of FUNDC1 in mitochondrial events and human diseases.Frontiers in cell and developmental biology · 2022
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. TXNIP/TBP-2: A Master Regulator for Glucose Homeostasis.Antioxidants (Basel, Switzerland) · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sally L ElshaerClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. selshaer@uthsc.edu.
Islam N MohamedClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. islam.mohamed@emory.edu.
Maha CouchaClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. mcoucha@southuniversity.edu.
Sara AltantawiClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. sara.m.altantawi@gmail.com.
Wael EldahshanClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. weldahshan@augusta.edu.
Megan L BartasiClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. mbartasis@gmail.com.
Ahmed Y ShanabClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. shanab79@gmail.com.
Renee LorysClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. rlorys@uga.edu.
Azza B El-RemessyClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 20912, USA. aelremessy@outlook.com.
University of Georgia · US

Funding

Molecular Mechanisms of diabetic retinopathyR01EY022408 · NEI · UNIVERSITY OF GEORGIA · PI EL-REMESSY, AZZA B · 2012 to 2016
$1.5M
NEI NIH HHS R01 EY022408
6 · The paper itself

Abstract

backgroundPrevious work demonstrated that high-fat diet (HFD) triggered thioredoxin-interacting protein (TXNIP) and that silencing TXNIP prevents diabetes-impaired vascular recovery. Here, we examine the impact of genetic deletion of TXNIP on HFD-impaired vascular recovery using hind limb ischemia model.

methodsWild type mice (WT, C57Bl/6) and TXNIP knockout mice (TKO) were fed either normal chow diet (WT-ND and TKO-ND) or 60% high-fat diet (WT-HFD and TKO-HFD). After four weeks of HFD, unilateral hind limb ischemia was performed and blood flow was measured using Laser doppler scanner at baseline and then weekly for an additional three weeks. Vascular density, nitrative stress, infiltration of CD68+ macrophages, and expression of inflammasome, vascular endothelial growth factor (VEGF), VEGF receptor-2 were examined by slot blot, Western blot and immunohistochemistry.

resultsBy week 8, HFD caused similar increases in weight, cholesterol and triglycerides in both WT and TKO. At week 4 and week 8, HFD significantly impaired glucose tolerance in WT and to a lesser extent in TKO. HFD significantly impaired blood flow and vascular density (CD31 labeled) in skeletal muscle of WT mice compared to ND but not in TKO. HFD and ischemia significantly induced tyrosine nitration, and systemic IL-1β and infiltration of CD68+ cells in skeletal muscle from WT but not from TKO. HFD significantly increased cleaved-caspase-1 and IL-1 β compared to ND. Under both ND, ischemia tended to increase VEGF expression and increased VEGFR2 activation in WT only but not TKO.

conclusionSimilar to prior observation in diabetes, HFD-induced obesity can compromise vascular recovery in response to ischemic insult. The mechanism involves increased TXNIP-NLRP3 (nucleotide-binding oligomerization domain-like receptor protein 3) inflammasome activation, nitrative stress and impaired VEGFR2 activation. Deletion of TXNIP restored blood flow, reduced nitrative stress and blunted inflammasome-mediated inflammation; however, it did not impact VEGF/VEGFR2 in HFD. Targeting TXNIP-NLRP3 inflammasome can provide potential therapeutic target in obesity-induced vascular complication.

Indexed as

high-fat diethind-limb ischemiainflammationthioredoxin interacting proteinvascular endothelial growth factor

Identifiers

PMID28661427
PMCPMC5618075
OpenAlexW2729857852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.